Wire · opportunities
Could tissue chips succeed where animal testing falls short?
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 23 August 2026 · Fusion42 review
University of Rochester researchers reached a key milestone with the FDA’s ISTAND pilot program for tissue chip technology, which offers a human-cell based alternative to animal testing for predicting immune-related side effects of cancer immunotherapies. If FDA-qualified, this technology could significantly improve drug safety assessment and streamline new drug application processes.
This Wire brief sits within Fusion42's coverage of Health.
◆ ◆ The Wire takeaway
You can tap into a pharma market opening as the FDA moves to accept tissue chips for drug safety testing. If your startup works on drug screening, now is the moment to connect with regulatory and pharma players before this technology scales.
◆ Coverage
1 source · 11 Aug 2026
◆ Related on Wire
◆ Topics